We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

VIPS:NYSEVipshop Holdings Limited Analysis

Data as of 2026-03-14 - not real-time

$16.00

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Vipshop (VIPS) trades at $16, below its 20‑day SMA of $16.80 and 50‑day SMA of $17.30, signaling a bearish short‑term bias. The RSI sits at 40.6, indicating the stock is not yet oversold, while the MACD histogram remains negative, reinforcing bearish momentum. Despite this, volume is increasing, suggesting accumulating interest. Volatility is elevated at nearly 39% over the past 30 days, and beta of 0.72 points to modest market sensitivity. Fundamentals show a low trailing PE of 7.8 and forward PE of 5.8, coupled with a dividend yield of 3.9% and a payout ratio under 25%, implying sustainable income. Recent earnings beat expectations (EPS $0.81 vs $0.78) even as revenue slipped 2.3% YoY, highlighting resilient profitability.
Analyst consensus remains positive with a “Buy” rating and a median target of $19.84, implying roughly 25% upside from current levels. The company holds $28.8 bn in cash against $6.4 bn of debt, providing a strong balance sheet to weather cyclical pressures. Gross margins of 23% and ROE of 17% indicate decent operational efficiency, while the dividend and cash generation support shareholder returns. However, exposure to China’s consumer sector introduces medium regulatory and high geographic risk. Overall, the stock appears undervalued relative to peers, offering a blend of value and modest growth characteristics.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • earnings beat with EPS surprise
  • increasing volume indicating accumulation
  • support level near $15.39

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • valuation gap with low PE and forward PE
  • ~25% upside to analyst target
  • sustainable dividend yield

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • strong cash position offsets cyclical exposure
  • regulatory and geographic headwinds in China
  • steady dividend supports long‑term income

Key Metrics & Analysis

Financial Health

Revenue Growth-2.30%
Profit Margin6.84%
P/E Ratio7.8
ROE17.23%
ROA6.61%
Debt/Equity14.51
P/B Ratio1.3

Technical Analysis

TrendBearish
RSI40.6
Support$15.39
Resistance$18.60
MA 20$16.80
MA 50$17.30
MA 200$17.39
MACDBearish
VolumeIncreasing
Fear & Greed Index72.88

Valuation

Target Price$20.10
Upside/Downside25.60%
GradeUndervalued
TypeBlend
Dividend Yield3.88%

Risk Assessment

Beta0.72
Volatility38.94%
Sector RiskMedium
Reg. RiskMedium
Geo RiskHigh
Currency RiskMedium
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.